VBI Vaccines (NASDAQ:VBIV) Earning Somewhat Critical Press Coverage, Accern Reports

Media coverage about VBI Vaccines (NASDAQ:VBIV) has trended somewhat negative on Thursday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. VBI Vaccines earned a coverage optimism score of -0.07 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.2041864613574 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several research analysts have recently weighed in on VBIV shares. Noble Financial reaffirmed a “buy” rating on shares of VBI Vaccines in a research note on Friday, March 23rd. Zacks Investment Research raised VBI Vaccines from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research note on Saturday, December 23rd. Finally, BidaskClub downgraded VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Three equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. VBI Vaccines presently has an average rating of “Hold” and an average target price of $8.75.

How to Become a New Pot Stock Millionaire

Shares of VBIV traded down $0.11 during trading hours on Thursday, hitting $3.52. 71,640 shares of the stock were exchanged, compared to its average volume of 115,567. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.26 and a current ratio of 5.32. VBI Vaccines has a 12-month low of $3.04 and a 12-month high of $5.53. The stock has a market capitalization of $225.39, a price-to-earnings ratio of -4.57 and a beta of 2.04.

WARNING: This article was first posted by BBNS and is the property of of BBNS. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://baseballnewssource.com/2018/04/05/vbi-vaccines-vbiv-getting-somewhat-negative-news-coverage-analysis-shows/2028861.html.

About VBI Vaccines

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Insider Buying and Selling by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.